Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, California (headquarters), San Diego, Seattle, Boston, New York, and London. For more information about Frazier Life Sciences, please visit www.frazierls.com.
Investment Stage: Series C; Series F
Portfolio 50
| Date | Name | Website | Total Raised | Location |
| 22.07.2026 | Crystalys ... | crystalystx.com | $130M | - |
| 08.01.2026 | Parabilis ... | parabilis.com | $305M | United Sta... |
| 21.05.2024 | Tubulis | tubulis.com | $629.54M | Germany |
| 21.05.2024 | Diagonal | diagonaltx.com | - | - |
| - | Aptinyx In... | aptinyx.com | $135M | United Sta... |
| - | Vaxcyte | vaxcyte.com | - | United Sta... |
| - | Calibrium | clbrm.com | - | - |
| - | Iovance Bi... | iovance.com | $172.5M | United Sta... |
| - | Bristol My... | bms.com | - | United Sta... |
| - | Seraxis | seraxis.com | $40M | United Sta... |
Show more
Persons 69
| Date | First Name | Last Name | Title | Location | |||
| - | Nicole | Shannon | Senior Fun... | linkedin.c... | - | - | - |
| - | Don | Frail, Ph.... | Senior Adv... | linkedin.c... | - | - | - |
| - | Kiah | Williams, ... | Associate | linkedin.c... | - | - | - |
| - | Lin | Mu, M.D., ... | Senior Ass... | linkedin.c... | - | - | - |
| - | Patrick | Heron | Managing P... | linkedin.c... | - | - | - |
| - | Kate | Schykeryne... | Investor R... | linkedin.c... | - | - | - |
| - | Anna | H. Chen, P... | Principal | linkedin.c... | - | - | - |
| - | Azmi | Nabulsi, M... | Entreprene... | linkedin.c... | - | - | - |
| - | Ali | Jackson | Counsel – ... | linkedin.c... | - | - | - |
| - | Stacy | Clark | Office Man... | linkedin.c... | - | - | - |
Show more
Mentions in press and media 12
| Date | Title | Description |
| 22.07.2026 | Crystalys Therapeutics Raises $130 Million To Bring Late-Stage Gout Drug To U.S. Market | Crystalys Therapeutics raises $130 million in an oversubscribed Series B financing round. The funding will help Crystalys take its late-stage gout drug to market. Series B comes less than a year after its impressive $205 million Series A of... |
| 26.06.2026 | RQ Bio Raises $115 Million Series A To Advance Influenza Prevention Antibody Program | RQ Bio announced that it has completed an oversubscribed $115 million Series A financing round. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph, and Wellington Mana... |
| 08.04.2026 | Sidewinder Therapeutics: $137 Million Raised For Bispecific ADC Cancer Therapies | Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clin... |
| 12.01.2026 | Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion | HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticke... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| 15.10.2025 | Tubulis Raises €308M In Series C Funding | Tubulis, a Munich, Germany-based oncology company, closed a €308 million (USD 361m) Series C financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Asce... |
| 01.08.2025 | Frazier Life Sciences: $1.3 Billion Venture Fund Closed | Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s... |
| 03.03.2025 | Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept | Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with signif... |
Show more